Investment Rating - The report maintains a "Recommended" rating for the company [3][6]. Core Insights - The company achieved a revenue of 1.447 billion yuan in 2024, representing a year-on-year increase of 85.40%, and a net profit attributable to shareholders of 733 million yuan, up 144.65% year-on-year [1]. - The company continues to expand its product pipeline in the medical aesthetics sector, launching the world's first eye-area anti-aging regeneration material based on "self-assembling root technology" [2]. - The company is actively expanding into international markets, enhancing brand recognition and competitiveness through participation in global exhibitions and securing patents in multiple countries [3]. Financial Performance - The company forecasts revenues of 1.445 billion, 1.918 billion, and 2.381 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 85.2%, 32.7%, and 24.2% [3][5]. - The net profit attributable to shareholders is projected to be 737 million, 1.007 billion, and 1.284 billion yuan for the same years, with growth rates of 145.7%, 36.8%, and 27.5% [3][5]. - The report indicates a PE ratio of 27, 20, and 16 for the years 2024, 2025, and 2026, respectively [3][5].
锦波生物：2024年业绩快报点评：业绩贴近预告上限，高质增长有望延续-20250226